Opportunity ID: 334753

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-21-265
Funding Opportunity Title: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jul 16, 2021
Last Updated Date: Jul 16, 2021
Original Closing Date for Applications: Apr 05, 2024
Current Closing Date for Applications: Apr 05, 2024
Archive Date: May 11, 2024
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

Additional Information

Agency Name: National Institutes of Health
Description: (Reissue of PAR-18-665) This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support clinical trials for projects that were previously funded by NIH SBIR and STTR Phase II awards. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of SBIR Phase II projects to the commercialization stage by promoting partnerships between NIH’s SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-21-265.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
grantsinfo@nih.gov
Email:grantsinfo@nih.gov

Version History

Version Modification Description Updated Date

Folder 334753 Full Announcement-PAR-21-265 -> PAR-21-265-Full-Announcement.pdf

Packages

Agency Contact Information: NIH OER Webmaster
grantsinfo@nih.gov
Email: grantsinfo@nih.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-F Use for due dates on or before January 24, 2022 PKG00268219 Aug 05, 2021 Jan 24, 2022 View
FORMS-G Use for due dates on or before January 24, 2023 PKG00270951 Dec 16, 2021 Jan 24, 2023 View
FORMS-H Use for due dates on or after January 25, 2023 PKG00278356 Nov 14, 2022 Apr 05, 2024 View

Package 1

Mandatory forms

334753 RR_SF424_2_0-2.0.pdf

334753 PHS398_CoverPageSupplement_5_0-5.0.pdf

334753 RR_OtherProjectInfo_1_4-1.4.pdf

334753 PerformanceSite_2_0-2.0.pdf

334753 RR_KeyPersonExpanded_2_0-2.0.pdf

334753 RR_Budget_1_4-1.4.pdf

334753 PHS398_ResearchPlan_4_0-4.0.pdf

334753 SBIR_STTR_Information_1_3-1.3.pdf

334753 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

334753 RR_SubawardBudget30_1_4-1.4.pdf

334753 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

334753 RR_SF424_5_0-5.0.pdf

334753 PHS398_CoverPageSupplement_5_0-5.0.pdf

334753 RR_OtherProjectInfo_1_4-1.4.pdf

334753 PerformanceSite_4_0-4.0.pdf

334753 RR_KeyPersonExpanded_4_0-4.0.pdf

334753 RR_Budget_3_0-3.0.pdf

334753 PHS398_ResearchPlan_4_0-4.0.pdf

334753 SBIR_STTR_Information_3_0-3.0.pdf

334753 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

334753 RR_SubawardBudget30_3_0-3.0.pdf

334753 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 3

Mandatory forms

334753 RR_SF424_5_0-5.0.pdf

334753 PHS398_CoverPageSupplement_5_0-5.0.pdf

334753 RR_OtherProjectInfo_1_4-1.4.pdf

334753 PerformanceSite_4_0-4.0.pdf

334753 RR_KeyPersonExpanded_4_0-4.0.pdf

334753 RR_Budget_3_0-3.0.pdf

334753 PHS398_ResearchPlan_5_0-5.0.pdf

334753 SBIR_STTR_Information_3_0-3.0.pdf

334753 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

334753 RR_SubawardBudget30_3_0-3.0.pdf

334753 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-11T14:53:44-05:00

Share This Post, Choose Your Platform!

About the Author: